About: Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997–2013 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997–2013
Creator	Hayward, Andrew Atun, Rifat Head, Michael Fitchett, Joseph Kumari, Nina Nageshwaran, Vaitehi
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Infectious diseases account for a significant global burden of disease and substantial investment in research and development. This paper presents a systematic assessment of research investments awarded to UK institutions and global health metrics assessing disease burden. METHODS: We systematically sourced research funding data awarded from public and philanthropic organisations between 1997 and 2013. We screened awards for relevance to infection and categorised data by type of science, disease area and specific pathogen. Investments were compared with mortality, disability-adjusted life years (DALYs) and years lived with disability (YLD) across three time points. FINDINGS: Between 1997–2013, there were 7398 awards with a total investment of £3.7 billion. An increase in research funding across 2011–2013 was observed for most disease areas, with notable exceptions being sexually transmitted infections and sepsis research where funding decreased. Most funding remains for pre-clinical research (£2.2 billion, 59.4%). Relative to global mortality, DALYs and YLDs, acute hepatitis C, leishmaniasis and African trypanosomiasis received comparatively high levels of funding. Pneumonia, shigellosis, pertussis, cholera and syphilis were poorly funded across all health metrics. Tuberculosis (TB) consistently attracts relatively less funding than HIV and malaria. INTERPRETATION: Most infections have received increases in research investment, alongside decreases in global burden of disease in 2013. The UK demonstrates research strengths in some neglected tropical diseases such as African trypanosomiasis and leishmaniasis, but syphilis, cholera, shigellosis and pneumonia remain poorly funded relative to their global burden. Acute hepatitis C appears well funded but the figures do not adequately take into account projected future chronic burdens for this condition. These findings can help to inform global policymakers on resource allocation for research investment.
has issue date	2015-12-17(xsd:dateTime)
bibo:doi	10.1016/j.ebiom.2015.12.016
bibo:pmid	26870829
has license	cc-by-nc-nd
sha1sum (hex)	3e0347a1ad5e2c0f00755537de9288bc9e3261a9
schema:url	https://doi.org/10.1016/j.ebiom.2015.12.016
resource representing a document's title	Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997–2013
has PubMed Central identifier	PMC4739409
has PubMed identifier	26870829
schema:publication	EBioMedicine
resource representing a document's body	covid:3e0347a1ad5e2c0f00755537de9288bc9e3261a9#body_text
is schema:about of	named entity 'syphilis' named entity 'translational research' named entity 'Ebola' named entity 'chlamydia' named entity 'infectious diseases' named entity 'Acute hepatitis' named entity 'syphilis' named entity 'acute hepatitis' named entity 'leishmaniasis' named entity 'YLD' named entity 'antimicrobial resistance' named entity 'Biotechnology and Biological Sciences Research Council' named entity 'pre-clinical' named entity 'dracunculiasis' named entity 'ResIn' named entity 'GBD' named entity 'Department of Health' named entity 'disease burden' named entity 'disease eradication' named entity 'UK Department of Health' named entity 'disease burden' named entity 'cholera' named entity 'Campylobacter' named entity 'DALY' named entity 'infectious disease' named entity 'global burden of disease' named entity 'pertussis' named entity 'Infectious Disease Research' named entity 'biotechnology' named entity 'MGH' named entity 'disease burden' named entity 'trypanosomiasis' named entity 'MGH' named entity 'data management' named entity 'pre-clinical' named entity 'Wellcome Trust' named entity 'public health' named entity 'Candida' named entity 'Wellcome Trust' named entity 'filoviruses' named entity 'DALYs' named entity 'leishmaniasis' named entity 'infection' named entity 'Shigellosis' named entity 'data analysis' named entity 'antiviral' named entity 'antibacterial' named entity 'Guinea worm' named entity 'Kenya' named entity 'cholera' named entity 'research funding' named entity 'influenza' named entity 'Vaccine-preventable diseases' named entity 'vaccine' named entity 'peer-reviewed' named entity '2011-2013' named entity 'ethics' named entity 'pneumonia' named entity 'HPV' named entity 'gastroenterology' named entity 'YLD' named entity 'YLD' named entity 'health research' named entity 'ResIn' named entity 'public health' named entity 'exchange rate' named entity 'Ebola outbreak in West Africa' named entity 'research institutions' named entity 'YLD' named entity 'CDC' named entity 'GBD' named entity 'malaria' named entity 'clinical practice' named entity 'African trypanosomiasis' named entity 'tuberculosis' named entity 'clinical science'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software